CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as $39.50 and last traded at $40.2720, with a volume of 1,289,943 shares trading hands. The stock had previously closed at $40.19.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on CRSP shares. Wall Street Zen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. HC Wainwright reissued a "buy" rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. UBS Group began coverage on CRISPR Therapeutics in a report on Thursday, October 15th. They set a "neutral" rating and a $52.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. Finally, William Blair raised CRISPR Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $72.93.
View Our Latest Report on CRISPR Therapeutics
CRISPR Therapeutics Stock Down 3.7%
The company has a market cap of $3.75 billion, a P/E ratio of -8.16 and a beta of 1.92. The company has a debt-to-equity ratio of 0.36, a quick ratio of 16.21 and a current ratio of 16.21. The business's fifty day moving average is $51.23 and its two-hundred day moving average is $52.35.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The company had revenue of $12.67 million during the quarter, compared to the consensus estimate of $14.75 million. The business's quarterly revenue was up 1311.1% on a year-over-year basis. Equities analysts predict that CRISPR Therapeutics AG will post -4.54 EPS for the current year.
Insider Transactions at CRISPR Therapeutics
In other CRISPR Therapeutics news, Director Simeon George sold 14,514 shares of CRISPR Therapeutics stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the sale, the director directly owned 15,486 shares of the company's stock, valued at $768,570.18. The trade was a 48.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ali Behbahani sold 13,679 shares of the company's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the sale, the director owned 16,637 shares of the company's stock, valued at $949,806.33. This represents a 45.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 93,558 shares of company stock worth $4,881,663 over the last three months. Company insiders own 5.20% of the company's stock.
Hedge Funds Weigh In On CRISPR Therapeutics
Several institutional investors have recently made changes to their positions in the company. Algert Global LLC raised its holdings in shares of CRISPR Therapeutics by 7.3% in the 3rd quarter. Algert Global LLC now owns 70,660 shares of the company's stock valued at $3,909,000 after purchasing an additional 4,780 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth approximately $223,000. Entropy Technologies LP boosted its stake in shares of CRISPR Therapeutics by 774.2% during the third quarter. Entropy Technologies LP now owns 98,090 shares of the company's stock valued at $5,426,000 after purchasing an additional 86,870 shares in the last quarter. FORA Capital LLC boosted its stake in shares of CRISPR Therapeutics by 455.2% during the third quarter. FORA Capital LLC now owns 31,469 shares of the company's stock valued at $1,740,000 after purchasing an additional 25,801 shares in the last quarter. Finally, Lionhunter Capital Management LLC bought a new position in shares of CRISPR Therapeutics during the third quarter valued at approximately $498,000. Hedge funds and other institutional investors own 69.20% of the company's stock.
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.